Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML
-
- STATUS
- Recruiting
-
- End date
- Dec 30, 2022
-
- participants needed
- 100
-
- sponsor
- Ge Zheng
Summary
Rencent years have witnessed great progress of the treatment of acute myeloid leukemia. However, most patients have poor outcomes following the currently first-line DA(daunorubicin, cytarabine)/IA(Idarubicin, cytarabine) chemotherapy, espiecially for the older patients and those not eligiable for receiving allo-HSCT. Azacitidine (AZA) was listed to methylation of drugs in China in 2018, is currently the only one approved methylation drugs in the treatment of AML(acute myeloid leukemia), in the NCCN guidelines. The homoharringtonie could induce AML(acute myeloid leukemia) cell lines and primary myeloid leukemia cell apoptosis, and the effect was dose dependent. While, HHT could also induce leukemia cells to differentiate into normal state, eventually achieve the goal of treatment, and control the disease. The investigators conducted a clinical study to evaluate the efficacy and safety of the AZA plus HAG(homoharringtonie, cytarabine, G-CSF), HIA(homoharringtonie, Idarubicin, cytarabine)/HDA(homoharringtonie, daunorubicin, cytarabine). This study is aimed to validate the efficacy and safety advantages of the regimens that cotain homoharringtonie and azacitidine, and to determine which regimen would receive more living benefits.
Description
Currently, the treatment of acute myeloid leukemia still remains a therapeutic challenge. Patients received traditional chemotherapy have a low remission rate, poor prognosis and short survival period for patients. New treatment strategies are needed in find out a better chemotherapy regimen.
Azacitidine (AZA) was listed to methylation of drugs in China in 2018, is currently the only approved drug for use in acute myeloid leukemia to methylation of drugs, in the NCCN guidelines. New combinations based on the azacitidine are currently undergoing, and the preliminary results brought new hope to the treatment of AML.
The homoharringtonie was extracted from tricuspid plants of China. As a protein synthesis inhibitor, homoharringtonie plays a major role in the G1 / G2 phase in cells. In addition, it could induce AML cell lines and primary myeloid leukemia cell apoptosis, and the effect was dose dependent. Meanwhile it could also induce leukemia cells to differentiate into normal state, eventually controlled the progression of the disease.
Combination with azacitidine may become a new option.This study intends to apply azacitidine in combination with homoharringtonie for treating AML patients, aiming to improve the efficacy, reducing adverse reactions and improve the living qualities of patients.
Patients of denovo or relapsed AML(age≥60y) will receive AZA+HAG (homoharringtonie, cytarabine, G-CSF) regiment as induction therapy. After complete remission(CR), maintenance therapy with AZA+lenalidomide/AZA will be used every 4-6 weeks until progression or total of 12cycles.
Patients of denovo or relapsed AML(age<60y) will receive AZA +HIA(homoharringtonie, Idarubicin, cytarabine) or AZA+HDA(homoharringtonie, daunorubicin, cytarabine) regiments as introduction therapy., After CR, post-remission therapy will follow with NCCN guidelines.
The investigators choose historical AML patients receiving tranditional chemotherapy as a control group, to validate the efficacy and safety profiles.
Details
| Condition | Acute Myeloid Leukemia |
|---|---|
| Treatment | Azacitidine, Homoharringtonine |
| Clinical Study Identifier | NCT04248595 |
| Sponsor | Ge Zheng |
| Last Modified on | 15 May 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer